Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KamRAB- HRIG · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 20 IU/kg KamRAB + Active Anti-Rabies Vaccine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| KamRAB - HRIG | DRUG | wound infiltration or IM injection |
Inclusion Criteria: * Healthy children (male and female) ages 0 months to \<17 years. * Have been exposed or possibly exposed to rabies. * Are indicated to receive post-exposure prophylaxis (PEP) against rabies infection. * Have documented informed consent from the child's parent(s) or legal guardi...
KamRAB-HRIG is used for rabies, specifically as a post-exposure treatment in children who have been exposed to the rabies virus. It is administered as a single dose along with an active rabies vaccine. The drug is currently in Phase 3 clinical development and is being studied for this indication.
KamRAB-HRIG is developed by Kamada Ltd., a biopharmaceutical company. The company's stock ticker is KMDA. Kamada Ltd. is conducting clinical trials to evaluate the safety and efficacy of KamRAB-HRIG for the treatment of rabies exposure.
KamRAB-HRIG is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trial for KamRAB-HRIG has been completed, and the drug is being studied for use in rabies post-exposure prophylaxis.
KamRAB-HRIG has one completed Phase 3 clinical trial with the identifier NCT02912845. This trial was a post-marketing study that evaluated KamRAB administered as a single dose with an active rabies vaccine in children exposed to rabies. The study was conducted in the United States and enrolled 30 participants.
KamRAB-HRIG is also known as KamRAB. The drug is referred to by both names in clinical research, with KamRAB being the shorter form used in the trial title. Both names refer to the same investigational product being developed by Kamada Ltd. for rabies post-exposure prophylaxis.